Immuneering (NASDAQ:IMRX) Issues Quarterly Earnings Results

Immuneering (NASDAQ:IMRX) released its earnings results on Tuesday. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.05, Yahoo Finance reports.

Immuneering Stock Performance

Immuneering stock traded down $0.10 during midday trading on Wednesday, reaching $1.14. The stock had a trading volume of 839,182 shares, compared to its average volume of 950,029. The firm’s fifty day simple moving average is $1.31 and its 200-day simple moving average is $2.87. Immuneering has a 1-year low of $1.05 and a 1-year high of $10.47. The stock has a market capitalization of $33.80 million, a P/E ratio of -0.61 and a beta of -0.61.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on IMRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of Immuneering in a research report on Wednesday. Chardan Capital dropped their price target on Immuneering from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Wednesday. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $12.60.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.